- 26 different customers representing North America, Asia and Europe
- 33 oral presentations across four consecutive days
- 69 scientific posters will be featured in a virtual exhibition hall
- Topics span the application of optical genome mapping (OGM) in research applications in cancer, cell and gene therapy, and genetic diseases
SAN DIEGO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc (Nasdaq: BNGO) today announced its 2024 Symposium lineup of 33 oral presentations delivered by 26 different customers worldwide featuring the utility of optical genome mapping (OGM) across a wide range of research applications in cancer, cell and gene therapy, and genetic disease. 2024 Symposium will take place virtually from January 22 to 25, 2024. During these four days, customers will showcase their latest research findings using OGM. Each day will feature user presentations, a live panel with Q&A, and scientific posters within the virtual exhibition hall. On day 2, Bionano will unveil a new product expected to advance cytogenetics and structural variant analysis.
“We believe 2024 Symposium is an opportunity for the OGM community to come together and share the progress they are making in translational research using OGM alongside other genome analysis tools,” said Erik Holmlin, PhD, president and chief executive officer of Bionano Genomics. “Symposium provides a chance for anyone interested or currently working with OGM to form connections within the community and see the potential impact of looking at the genome in a different way. We believe this year’s event will be our best to date, with an expanded focus on the use of OGM in cell and gene therapy, as well as some very exciting product announcements that will drive further research advancements.”
“Our 2023 Symposium was a fantastic event where OGM users shared their data covering genetic disorder and cancer research. Since then, we have made significant improvements in our end-to-end workflow which we believe has enabled our customers to advance their clinical and translational research. The presentations at this year’s event have been elevated to a new level, with dedicated sessions on advancements in heme malignancy research and solid tumor analysis, updates from global consortia driving OGM adoption, and new OGM data from researchers focused on solving constitutional diseases and rare disease,” said Alka Chaubey, PhD, FACMG, chief medical officer at Bionano. “Symposium attendees have a unique opportunity to learn from their peers, network, and view scientific posters and new products that we will showcase each day.”
Each session of Symposium will start at 7:00 am PST and will last approximately 3 hours. After the scientific presentations, the speakers will join for a live panel discussion and Q&A moderated by Dr. Chaubey. In addition, each day will feature a scientific poster exhibit. Below is the list of customer presentations for each day and the application area.
January 22: New Standards in Hematological Malignancies
| Speaker | Institution | Title |
| Dr. Tiffany Clouston | Saint John Regional Hospital | Optical Genome Mapping: Pivoting Towards a New Technology |
| Dr. Ying Zou | Johns Hopkins University School of Medicine | Comprehensive Genome-wide Genetic Profile in Plasma Cell Neoplasm by OGM |
| Dr. Guilin Tang | University of Texas MD Anderson Cancer Center | Optical Genome Mapping (OGM) in T-lymphoblastic Leukemia (T-ALL) |
| Dr. Yanming Zhang | Memorial Sloan Kettering Cancer Center | Clinical Research Applications of Optical Genome Mapping (OGM) in Cancer Cytogenetics |
| Dr. Agnes Daudignon | Lille Hospital | FrOGG: French Speaking OGM Group from GFCH |
| Dr. Adam Smith | University of Toronto | The "Framework" for the Clinical Research Implementation of Optical Genome Mapping in Hematologic Malignancies |
| Daniel Saul | Bionano | Advancements in Informatics and Software for OGM Data Analysis |
January 23: New Frontiers in Oncology
| Speaker | Institution | Title |
| Dr. Marc-Henri Stern | Institut Curie | Features of Homologous Recombination Deficiency (HRD) in Solid Tumors Using Optical Genome Mapping |
| Dr. Isabelle Raymound-Bouchard | Hôpital Maisonneuve-Rosemont | Developing Optical Genome Mapping for CD 138+ Plasma Cells |
| Dr. Scott Ryall | Brigham and Women’s Hospital | Illuminating a New Path Forward for Cancer Research |
| Dr. Ravindra Kolhe | Augusta University | Novel Biomarkers Unveiled by Utilization of OGM in Cancer Investigations |
| Dr. Trilochan Sahoo | Bionano Laboratories | A Prospective Study of Optical Genome Mapping in Hematologic Malignancies |
| Dr. Deb Tweddle | Newcastle University | Novel Structural Variants Detected by Optical Genome Mapping in Neuroblastoma |
| Dr. Miriam Bornhorst | Lurie Children’s Hospital of Chicago | Application of Optical Genome Mapping for Pediatric Brain Tumors: Solving Challenging Cases |
| Dr. Adrian Dubuc | Roswell Park Comprehensive Cancer Center | Raising the Bar: Comprehensive Cytogenetic Profiling for Improved Lymphoma Analysis |
| Darisha Jiandani | Bionano | The Next Major OGM Advancement: Unlocking Flexible Structural Variant Analysis at Scale |
January 24: Advances in Constitutional Applications
| Speaker | Institution | Title |
| Dr. Roger Stevenson | Equinamitas | Optical Genome Mapping for Prenatal Genetic Testing – Multisite Evaluation and Validation |
| Dr. Roger Stevenson | Equinamitas | Detection of Constitutional Structural Variants by Optical Genome Mapping – A Multisite Study of Postnatal Samples |
| Dr. Nikhil Sahajpal | Greenwood Genetic Center | Optical Genome Mapping in Rare Disorders |
| Dr. Noemi Buisset | Medicover Genetics | Insights from Optical Genome Mapping: Uncovering Discrepancies in Chorionic Villi STC and LTC |
| Dr. Laila El Khattabi | AP-HP Sorbonne | The CHROMAPS study: First Results from Optical Genome Mapping |
| Dr. Maria Clara Bonaglia | Scientific Institute E. Medea | Optical Genome Mapping (OGM): Refining Genotype Phenotype Correlation in Different Types of Structural Variants |
| Dr. Yassmine Akkari | Nationwide Children’s Hospital | Optical Genome Mapping (OGM) Identifies Multiple Structural Variants in a Case with Atypical Phelan-McDermid Syndrome |
| Dr. Ulrich Brockel | Medical College of Wisconsin | Optical Genome Mapping for Constitutional Chromosome Analysis |
| Dr. Madhuri Hegde | Revvity | Molecular Analysis of Facioscapulohumeral Muscular Dystrophy Using Optical Genome Mapping |
| Tanushi Sahai | Bionano | The Sample Preparation Landscape for Optical Genome Mapping |
January 25: OGM in Cell and Gene Therapy
| Speaker | Institution | Title |
| Dr. Alex Hastie | Bionano | Detection of CRISPR Related Structural Variants in Genome Edited Hematopoietic Stem Cells in X-SCID Disease |
| Dr. Sam Dougaparsad | Bionano | Optical Genome Mapping: Revolution in Quality Control for Cell Genomic Integrity |
| Dr. John Yu | Chang Gung Memorial Hospital | Whole Genomic Analysis Reveals Atypical Non-Homologous Off-target Large Structural Variants Induced by CRISPR-Cas9-mediated Genome Editing |
| Dr. Samantha Maragh | National Institute of Standards and Technology | Initial Outcomes of Variant Detection and Quantitation from the First NIST Genome Editing Consortium Interlab Study |
| Dr. Andy Pang | Bionano | Genome Integrity QC Using Optical Genome Mapping – A Technical Guide |
| Owen Pearce | eGenesis | Engineering Porcine Genomes for Xenotransplantation: Detecting Structural Variants in Engineered Genomes Using Optical Genome Mapping |
| Dr. Saumyaa Saymyaa | AstraZeneca | Applications of OGM in Cell and Gene Therapy |
Symposium registration is open to all and there is no charge for attending this event. Register today at https://bionanosymposium2024.vfairs.com/.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis technology. For more information, visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements of Bionano
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the anticipated benefits of the 2024 Symposium, the potential for OGM to be adopted for applications discussed at the 2024 Symposium, and the ability and utility of OGM to be adopted for applications in genetic disease and cancer research and for cell and gene therapy and other applications discussed at the 2024 Symposium. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of geopolitical and macroeconomic developments, such as recent and future bank failures, the ongoing Ukraine-Russia conflict, related sanctions, the Israel-Hamas war, and any global pandemics, on our business and the global economy; challenges inherent in developing, manufacturing and commercializing products; our ability to further deploy new products and applications and expand the markets for our technology platforms; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of future study results to support those reported and discussed at the 2024 Symposium; future study results that contradict the results discussed and reported at the 2024 Symposium; failure of OGM to be adopted for applications in genetic disease and cancer research and for cell and gene therapy and other applications discussed at the 2024 Symposium; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general; our expectations and beliefs regarding future growth of the business and the markets in which we operate; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern”; and including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We are under no duty to update any of these forward-looking statements after the date they are made to conform these statements to actual results or revised expectations, except as required by law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date the statements are made. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this press release.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
David Holmes
Gilmartin Group
+1 (858) 888-7625
IR@bionano.com
